Pharmaceutical-grade research peptides with ≥99% purity, third-party verified and dispatched from our UK facility. Trusted by researchers across Britain.
Retatrutide (LY3437943) is a next-generation triagonist peptide simultaneously targeting GIP, GLP-1, and glucagon receptors. It represents one of the most significant advances in metabolic research peptide science, with multiple Phase III trials underway globally.